BOCA RATON, Fla., Oct. 25, 2017 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and keloids with Superficial Radio Therapy (SRT), announces that management will hold a conference call on Thursday, November 2, 2017 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2017. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
To access the conference call, the dial-in numbers are (844) 666-7589 (U.S. Toll Free), and (443) 961-0433 (International). All listeners should provide the operator with the following conference ID: 1678917.
Following the conclusion of the conference call, a replay will be available through November 8, 2017 and can be accessed by dialing (855) 859-2056 (U.S. Toll Free), (404) 537-3406 (International). All listeners should provide the operator with the following conference ID: 1678917. The call will also be archived on the Company’s website for a period of time at www.sensushealthcare.com.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit www.sensushealthcare.com.
Contact:
LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
View original content:https://www.prnewswire.com/news-releases/sensus-healthcare-to-host-third-quarter-2017-financial-results-and-business-update-conference-call-on-november-2-2017-300542921.html
SOURCE Sensus Healthcare